Suffering from Shingles? Shake Off Symptoms with Cannabinoid Products!
According to the Center for Disease Control 1 in 3 people in the U.S. will develop Shingles in their lifetime. Approximately 1 million cases reported per year as a result. Unfortunately this condition is incredibly common and incredibly transmittable. Shingles is a Viral infection caused by the Varicella-Zoster Virus, the same virus responsible for Chickenpox. The virus can enter the nervous system and lie dormant for years. Eventually, this infection will reactivate and travel along nerve pathways to the skin.
Case to case reasons for this reactivation differ, but professionals suggest one common cause; lowered immune function. Lowered Immune functions connected to medications such as steroids and drugs given after transplantation, and certain cancers like leukemia and lymphoma commonly appear in cases of Shingles Virus reactivation. This reemergence in the system provokes a range of symptoms such as rashes with blisters, itching, pain and inflammation, sensitivity, and less commonly fever, headache, fatigue, and sensitivity to light.
“This virus can be transmitted easily and those who have not been vaccinated are more susceptible to infection than those who have.”
Cannabinoids Provide a Variety of Benefits
Shingles causes severe inflammation as well as painful rashes that can blister. Rooted in the nervous system, inflammation travels pathways to the skin leading to inflamed nerve endings and skin.
Cannabinoids stimulate or bond to receptors to regulate or modulate physiological processes such as sleep, hunger and yes, inflammation. CB1 Receptors are located in the Central Nervous System in the Brain Spine and connective tissues as well as gonads, glands, and certain organs. These receptors express involvement in the regulation of Neuropathic and Nerve Pain. Note that these CB1 Receptors also express involvement in Memory and Motor Functions.
Several Cannabinoids derived from the hemp plant relieve inflammation and pain. This is exhibited by the countless clinical studies and trials available to the public. These studies and trials laid the foundation of many medical patents filed in recent years.
One patent in particular outlines the anti-inflammatory benefits of Cannabidiol (CBD) in direct correlation to Shingles and several other conditions. United States Patent US20100273895A1 discusses the viability of a topical formulation containing CBD as a medicament for inflammatory symptoms. The patent discusses the analgesic and neuroprotective benefits as well as the ability to, reduce inflammation, help alleviate nausea and emesis, treat epilepsy, anxiety disorders, and glaucoma.
In 2008, double-blind, randomized clinical trial has been reported both high and low doses of inhaled cannabis reduced neuropathic pain of diverse causes in subjects unresponsive to standard pain therapies (Wilsey et al. 2008) Additionally, an international team of investigators from the UK, Belgium and Romania affirmed preclinical findings in a separate clinical study. They concluded: the THC/CBD extract showed a more promising efficacy profile than the THC extract alone ( Johnson et al. 2009).
In recent years, Cannabinoids have also exhibited antiviral benefits. In particular, Cannabichromene (CBC) has shown antiviral, antimicrobial, antibacterial, and antifungal benefits. The pharmacology community highly regards CBC for these reasons. In fact, all five major cannabinoids: cannabidiol, cannabichromene, cannabigerol, ∆9- tetrahydrocannabinol and cannabinol showed potent activity against a variety of methicillin-resistant Staphylococcus aureus (MRSA) strains (Appendino et al., 2008).
US Patent US6541510B2 provides a method, compounds, and compositions for inhibiting the replication or proliferation of a virus. This invention uses Cannabichromene to act as an anti-viral to treat the virus, host cell, or infected cell. This is occurs under conditions sufficient to inhibit the replication or proliferation of the virus. In fact several patents of similar content are available for review. All of them naming Cannabichromene as the antiviral constituent necessary to prohibit viral progression.
Both CB1 and CB2 Receptors are found in Immune Tissues. However, the level of expression of the CB2 gene in immune tissue appears to be 10-100 times higher than that of CB1. Meanwhile, the research carried out by the Scientific Community demonstrated the immune modulating effects of Cannabinoids such as CBD. In fact, a number of recent studies have demonstrated that the endocannabinoids may have some stimulatory impact on the immune system and may actually be important in homeostasis or control of immune reactions.
When the Immune System senses a threat, immune cells release certain proteins called Cytokines. Cytokines are regulators of host responses to infection, immune responses, inflammation, and trauma. Cytokines can serve two purposes. Pro-inflammatory types act to make disease worse, whereas anti-inflammatory types reduce inflammation and promote healing. Attention also has focused on blocking cytokines, which are harmful to the host, particularly during overwhelming infection.
Are Cannabinoid Products an Option for You?
Check out our Shop to find products that may help qualm your Shingles symptoms. Topical Salves offer quick relief for inflammation and pain. Conversely, Tincture Alternatives offer a systemic route to targeting CB2 Receptors in the Immune Tissues. Our Team is always available for help, just contact Us!